Last reviewed · How we verify
COM701
At a glance
| Generic name | COM701 |
|---|---|
| Sponsor | Compugen Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (PHASE1, PHASE2)
- COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (PHASE1)
- COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (PHASE1)
- COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COM701 CI brief — competitive landscape report
- COM701 updates RSS · CI watch RSS
- Compugen Ltd portfolio CI